Syntekabio Introduces AI Drug Discovery Innovations at UKC 2022
Syntekabio will showcase its AI drug discovery platforms, DeepMatcher® and NEO-ARS™, at the US-Korea Conference (UKC) 2022 on August 19 in Arlington, Virginia. This event aims to foster collaboration between American and Korean professionals in science and business, providing networking opportunities. The company’s Chief Scientific Officer, Kilyoung Kim, will present these innovations, reinforcing Syntekabio’s role in advancing transformative medicine through technology.
Syntekabio, a global leader in AI-driven drug discovery, is set to unveil its advanced cloud platforms, DeepMatcher® and NEO-ARS™, at the US-Korea Conference (UKC) 2022 on August 19 in Arlington, Virginia. This event aims to enhance collaboration between American and Korean communities in science and technology, enabling networking opportunities for aspiring entrepreneurs and business leaders. Kilyoung Kim, PhD, the Chief Scientific Officer and president of Syntekabio USA, will introduce the company’s latest innovations during the Innovative and Entrepreneurship Symposium.
The UKC promotes cooperative endeavors in technology and development, offering a platform for participant companies to showcase their promising products and cultivate cross-border business opportunities. Interested professionals can obtain specific details about the event at the provided web address. Syntekabio encourages media engagement following their presentation, with arrangements available for one-on-one meetings to discuss their offerings in-depth.
Founded in 2009 and headquartered in South Korea, Syntekabio specializes in artificial intelligence and big data applications to facilitate transformative drug discovery and development. The company’s commitment to international compliance reflects its goal of enhancing global health and advancing innovative treatments. For further information regarding their products, including DeepMatcher® and NEO-ARS™, prospective partners and clients can refer to the official website.
The upcoming UKC is poised to serve as a pivotal gathering to reinforce U.S.-Korea collaborations in the sciences and entrepreneurship sectors, highlighting innovations that could shape the future of healthcare. Syntekabio’s presence at this event underscores its dedication to leveraging technology for groundbreaking medical advancements, positioning itself as a frontrunner in the AI drug discovery arena.
The US-Korea Conference (UKC) serves as an essential platform for fostering collaboration among professionals across various scientific disciplines. This annual event invites entrepreneurs, researchers, and industry experts to share knowledge and address the latest technological developments. Syntekabio’s participation, particularly with the launch of its AI-powered drug discovery platforms, underscores the growing intersection of technology and healthcare, emphasizing global efforts to enhance treatment modalities and patient outcomes through innovative solutions.
In conclusion, Syntekabio’s presentation at the UKC 2022 is a significant milestone that showcases advanced AI drug discovery technologies. The event not only facilitates collaboration and networking but also highlights the role of innovation in addressing global health challenges. By introducing platforms such as DeepMatcher® and NEO-ARS™, Syntekabio reaffirms its commitment to pioneering advancements in drug development and therapeutic efficacy.
Original Source: www.globenewswire.com
